SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ — Aethlon Medical, Inc. (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit.
On September 18th, Sahil Shah of Exosome Sciences will give a presentation entitled: “Exosomes: A Multiplexed Platform for Clinical Management.”
On September 19th, Aethlon Medical CEO and ESI founder Jim Joyce will give a presentation entitled: “Extracorporeal Clearance of Tumor-Secreted Exosomes, An Adjunct Strategy to Improve Cancer Treatment Outcomes.”
The event is being held at the Town and Country Resort Hotel in San Diego, California. Additional details can be found online at: http://selectbiosciences.com/conferences/index.aspx?conf=SCAS2014.
About Exosome Sciences, Inc.
Exosome Sciences (ESI), a majority wholly owned subsidiary of Aethlon Medical, Inc., develops exosome-based solutions to improve identification and monitoring of acute and chronic conditions. Our candidate products are focused toward diagnostic advancements in the fields of oncology, infectious disease and brain injury. Exosomes represent an optimal diagnostic target as diseased or injured cells release these particles into body fluids such as urine, blood, saliva and cerebrospinal fluid where they can be accessed for analysis. Our exosome-based assays unlock the ability to identify proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive “liquid biopsies”. Additional information can be found at www.ExosomeSciences.com.
About Aethlon Medical, Inc.
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease and cancer. The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
James A. Joyce
Chairman and CEO
Chief Financial Officer